Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

Neal D. Shore(Carolina Urologic Research Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Tracy M. Downs(University of Wisconsin–Madison), Alan Boyd(University of Edinburgh), Seppo Ylä‐Herttuala(University of Eastern Finland), Robert S. Svatek(The University of Texas at San Antonio Health Science Center), Lawrence I. Karsh(The Urology Center of Colorado), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Yair Lotan(Southwestern Medical Center), Nigel Parker(University of Eastern Finland), Tracey L. Krupski(University of Virginia Cancer Center), Gillian Gregory(Thomas Jefferson University), Seth P. Lerner(Baylor College of Medicine), Brant A. Inman(Duke Medical Center), Kenneth Ogan, Michael Woods(University of Cambridge), Leonard G. Gomella(Thomas Jefferson University), Trinity J. Bivalacqua(University of Pennsylvania), Stephen A. Boorjian(Mayo Clinic), Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), F. Peter Treasure(Royal Statistical Society), David G. Sawutz, Robert L. Grubb(Washington University in St. Louis), Daniel Canter(Ochsner Medical Center)
Journal of Clinical Oncology
August 23, 2017
Cited by 175


Related Papers